Patents by Inventor BRYAN LINGGI

BRYAN LINGGI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-Specific Fusion Proteins
    Publication number: 20240101713
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: October 9, 2023
    Publication date: March 28, 2024
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 11814443
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: November 14, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20230322951
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 12, 2023
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 11673970
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 13, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-Specific Fusion Proteins
    Publication number: 20210214463
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 10988547
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: April 27, 2021
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20210040233
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 10858450
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 8, 2020
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-Specific Fusion Proteins
    Publication number: 20200048368
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 13, 2020
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 10407512
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 10, 2019
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20180237540
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 9982060
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: May 29, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-Specific Fusion Proteins
    Publication number: 20170335015
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: June 9, 2017
    Publication date: November 23, 2017
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Method of treating myocardial infarction by administering a bi-specific fusion protein
    Patent number: 9718892
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: August 1, 2017
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20160168269
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 16, 2016
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 9238080
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: January 19, 2016
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20140178380
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 26, 2014
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham Groton, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins for tissue repair
    Patent number: 8691771
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 8, 2014
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Publication number: 20110293579
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: May 20, 2011
    Publication date: December 1, 2011
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun Lippow
  • BI-SPECIFIC FUSION PROTEINS
    Publication number: 20110286976
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Applicant: MERRIMACK PHARMACEUTICALS
    Inventors: ULRIK NIELSEN, THOMAS WICKHAM, BIRGIT SCHOEBERL, BRIAN HARMS, BRYAN LINGGI, MATTHEW ONSUM, BYRON DELABARRE